Bicara plans Q3 alternative dosing study of ~150–200 patients as it targets mid-2027 interim analysis

Tech eyes recovery after selloff - What’s moving markets

2026/06/24

U.S. economy sees little kick from World Cup, Pantheon says

2026/06/24

3 Insurance Stocks We’re Skeptical Of

2026/06/24

Trainline shares drop as analysts weigh new CEO appointment from Flutter

2026/06/24